Liuqing Yang, PhD
Department of Molecular Oncology, Division of Discovery Science
About Liuqing Yang
I am committed to advancing immune-based cancer therapies by uncovering the molecular and cellular mechanisms that drive immune resistance. My laboratory focuses on defining novel molecules and pathways -including noncoding RNAs (ncRNAs), metabolic regulators, and neuronal-type signaling - that shape immune decision-making within the tumor microenvironment. By clarifying why immune responses succeed in some patients but fail in others, we aim to develop transformative therapeutic strategies. My research has generated a strong track record of impactful discoveries published in Nature , Cell , Science , Nature Immunology , Nature Cell Biology , Journal of Clinical Investigation , Science Translational Medicine , Science Advances , Cell Metabolism , and Immunity . Key findings include: a PTEN enzymatic switch driving EMT; the oncogenic lncRNA LINK-A suppressing tumor antigenicity and intrinsic tumor suppression to promote immune evasion in TNBC; ncRNAs mediating immune exclusion via the kynurenine pathway in pancreatic cancer; snoRNA–IL-15 crosstalk linking obesity to immune dysfunction; and T cell ferroptosis and chromatin introversion driving impaired anti-tumor immunity in renal medullary carcinoma and sickle cell disease. Collectively, these studies have established ncRNAs as critical regulators of tumor progression and immune resistance, and they point toward novel therapeutic strategies targeting immune–metabolic circuits.
Present Title & Affiliation
Primary Appointment
Faculty (Joint), The University of Texas MD Anderson UT Health Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas
Professor, Molecular Oncology, Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2006 | Georgia State University, Atlanta, Georgia, US, Ph.D. in Biological Science |
| 1998 | Xinjiang University, Urumqi, CN, BS in Biology |
Postgraduate Training
| 2006-2013 | Postdoctoral fellow, University of California, San Diego, La Jolla, California |
Experience & Service
Faculty Academic Appointments
Associate Professor, The University of Texas MD Anderson UT Health Houston Graduate School of Biomedical Sciences (GSBS), Houston, Texas, 2019 - 2025
Associate Professor, Molecular and Cellular Oncology, Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - 2025
Assistant Professor, Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2013 - 2019
Assistant Professor, Graduate School of Biomedical Sciences (GSBS), The University of Texas Health Science Center, Houston, TX, 2013 - 2019
Other Professional Positions
Consultant, Phenylketonuria Landscape, Capvision, New York, NY, 2024
Consultant, RNA modulator for Phenylketonuria (PKU) treatment, BioMarin Pharma, Inc, San Rafael, California, 2022
Consultant, Development of a RNA-based therapy for Phenylketonuria, BioMarin Pharma, Inc, San Rafael, California, 2021
Consultant, Oncogenic Noncoding RNA-Mediated Loss of Tumor Antigenicity and Immunotherapy Resistance, Ono Pharma USA, Inc, Lawrenceville, New Jersey, 2019
Intramural Institutional Committee Activities
Member, ADVANCE Committee, The University of Texas MD Anderson UT Health Houston Graduate School of Biomedical Sciences (GSBS), 2025 - 2025
Member, GSBS Admission Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Research Space Policy Revisions, The University of Texas MD Anderson Cancer Center, 2024 - 2024
Member, GSBS Student Scholarship Committee, The University of Texas MD Anderson UT Health Houston Graduate School of Biomedical Sciences (GSBS), 2020 - 2022
Member, BCB Program Examination Committee, The University of Texas MD Anderson UT Health Houston Graduate School of Biomedical Sciences (GSBS), 2020 - 2023
Interim Chair, Rodent Colony Management, The University of Texas MD Anderson Cancer Center, 2018 - 2023
Extramural Institutional Committee Activities
Member, AACR Gertrude B. Elion Cancer Research Grants Scientific Review Committee, American Association of Cancer Research, 2021 - 2024
Editorial Activities
I contribute by highlighting recent significant papers related to the field of noncoding RNA (ncRNA). This involves selecting research that advances our understanding of ncRNA mechanisms and their implications in various biological processes and diseases, thereby keeping the scientific community informed and fostering further research and discussion in this dynamic field, Non-Coding RNA, 2023
Honors & Awards
| 2023 | Julie and Ben Rogers Award Finalist for Excellence in Research, The University of Texas MD Anderson Cancer Center |
| 2022 | Wall of Science, The University of Texas MD Anderson Cancer Center |
| 2021 | Mentor for 2021 STAT Wunderkind Award Awardee, STAT News |
| 2021 | Research Townhall Scientific Highlights, The University of Texas MD Anderson Cancer Center |
| 2021 | Wall of Science, The University of Texas MD Anderson Cancer Center |
| 2020 | Sanofi-Cell Research Outstanding Research Article Award, Sanofi-Cell Research |
| 2020 | Faculty Scholar Award, The University of Texas MD Anderson Cancer Center |
| 2020 | Wall of Science, The University of Texas MD Anderson Cancer Center |
| 2019 | President's Recognition of Faculty Excellence Award, The University of Texas MD Anderson Cancer Center |
| 2019 | American Association of Cancer Research NextGen Stars, American Association of Cancer Research |
| 2018 | Andrew Sabin Family Fellowship, The University of Texas MD Anderson Cancer Center |
| 2018 | Wall of Science, The University of Texas MD Anderson Cancer Center |
| 2016 | Wilson S. Stone Memorial Award, The University of Texas MD Anderson Cancer Center |
| 2015 | Wall of Science, The University of Texas MD Anderson Cancer Center |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. The Impact of Noncoding RNA on Liver Metabolism and Tumor Microenvironment. Invited. Houston, Texas, US.
- 2024. Harnessing NonCoding RNAs: Emerging Targeted Therapies for Breast Cancer. Invited. Updates on Advanced Breast Cancer: Local Management and other New Perspectives. Houston, Texas, US.
- 2023. ncRNAs in Mitochondrial Stress Pathways. Invited. MD Anderson-Princess Margaret Joint Symposium on Cancer Metabolism. Houston, Texas, US.
- 2023. Deciphering Mechanisms: How Bladder Cancer Evades Immunotherapy. Invited. GU CCSG Retreat. Houston, Texas, US.
- 2021. A Noncoding RNA Modulator Potentiates Phenylalanine Metabolism. Invited. Research Town Hall. Houston, Texas, US.
- 2019. Long Noncoding RNAs: From Disease to Targeted Therapeutics. Invited. Department of Molecular and Human Genetics Research Seminar. Houston, Texas, US.
- 2019. Emerging Roles of Long Noncoding RNAs in Tumor Immune Microenvironment, Immunotherapy-related Cardiotoxicity and Cardiac Metastasis. Invited. Symposium on Cancer Research. Houston, TX, US.
- 2019. Long Noncoding RNAs: From Disease to Targeted Therapeutics. Invited. Experimental Therapeutics Distinguished Seminar Series. Houston, Texas, US.
- 2018. Progress, paradigms, and pathways of long non-coding RNAs in cancer. Invited. Molecular and Cellular Biology Seminar Series. Houston, Texas, US.
- 2016. LncRNA Wire Up Cancer Signaling," "Cancer Evolution: Mechanisms of Vulnerability and Resistance. Invited. Research Symposium: Cancer Evolution, Mechanisms of Vulnerability and Resistance. Houston, Texas, US.
- 2015. Functional Characterization of LncRNAs Contributing to Cancer Signaling. Invited. Grand Round in Oncology. Houston, Texas, US.
- 2015. Functional Characterization of LncRNAs Contributing Hippo-YAP Signaling. Invited. Cancer Biology Program Retreat. Houston, Texas, US.
- 2014. Illuminating Genomic Dark Matter "ncRNA in Disease and Cancer". Invited. Symposia on Cancer Research. Houston, TX, US.
- 2013. LncRNA-Dependent Mechanism of Androgen Receptor-regulated Gene Activation Programs and Its Implications in Castration-resistant Prostate Cancer. Invited. SCBA-Texas Chapter the 27th Annual Symposium. Houston, Texas, US.
Regional Presentations
- 2023. Innovating Breast Cancer RNA therapy: Mechanisms and Pharmaco-genetic Inhibitors. Invited. SABCS Breast Cancer Patient Reception. San Antonio, Texas, US.
- 2017. Progress, paradigms, and pathways of long non-coding RNAs in cancer. Invited. Educational Workshop. San Antonio, Texas, US.
National Presentations
- 2025. Modulating liver phenylalanine and neutrophil kainite receptors to shape the host-tumor interaction: mechanisms and strategies. Invited. Cancer and Metabolism 2025. Austin, Texas, US.
- 2024. Modulating Tumor Micro- and Macro-environments: Mechanisms and Strategies. Invited. Visiting Scientist Seminar. Lexington, KY, US.
- 2024. A noncoding RNA modulator potentiates phenylalanine metabolism in mice. Invited. Genetics Grand Round. Atlanta, GA, US.
- 2021. The Role of Long Noncoding RNAs in Muscular Dystrophy. Invited. Department of Integrative Biology & Physiology Seminar Series. Minneapolis, MN, US.
- 2019. New Players in Hippo-Yap Pathway. Invited. Special Conference on The Hippo Pathway: Signaling, Cancer, and Beyond. San Deigo, CA, US.
- 2019. Long noncoding RNA-directed Antigenicity Loss Suppresses Immunosurveillance. Invited. NextGen Stars Prsentation. Atlanta, GA, US.
- 2016. Unlocking Long Non-coding RNAs for Cancer Treatment. Invited. Geoffrey Rosenfeld Symposium. San Diego, CA, US.
- 2016. Unlocking Phospholipid-binding Long Non-coding RNAs for Breast Cancer Treatment. Invited. SU2C Innovative Research Grants Selection Meeting. Philadelphia, PA, US.
International Presentations
- 2022. Plumbing Mysterious RNAs in “Dark Genome” for the Conquest of Human Diseases. Invited. 14th International Congress of Cell Biology & 9th Asian Pacific Organization for Cell Biology Joint Meeting. Taipei, TW.
- 2022. Mechanisms and Management of Cancer Immunotherapy-induced Myocarditis and Resistance. Invited. International Conference on Advanced Biomedical Sciences HERO Symposium. Taichung, TW.
- 2017. Progress, Paradigms, and Pathways of Long non-coding RNAs in Cancer. Invited. The 2nd Forum on Signaling Pathways and Non-coding RNAs in Carcinogenesis, Prevention and Therapy of Malignant Tumors. Washington DC, US.
- 2015. Functional Characterization of LncRNAs Contributing to Cancer Signaling. Invited. The 2nd Asian Pacific Conference of Tumor Biology and Medicine. Nanjing, CN.
- 2015. LncRNA Binds PtdIns (3,4,5)P₃ to Activate Normoxic HIF1α Signaling in Triple-negative Breast Cancer. Invited. Distinguished Seminar Series. Nanjing, CN.
Grant & Contract Support
| Date: | 2025 - 2028 |
| Title: | Targeting Neuronal Mimicry in SMARCB1-Deficient Renal Medullary Carcinoma Treatment |
| Funding Source: | DOD/Kidney Cancer Research Program |
| Role: | PI |
| ID: | KC240237/HT94252510882 |
| Date: | 2024 - 2029 |
| Title: | Elucidating T Cell Ferroptosis in Renal Medullary Carcinoma: 3D Genome Architecture Rewiring and Therapeutic Alleviation |
| Funding Source: | NIH/NCI |
| Role: | Contact Principal Investigator |
| ID: | R01CA285454-01A1 |
| Date: | 2023 - 2028 |
| Title: | Molecular Mechanism of long Noncoding RNAs in Phenylketonuria |
| Funding Source: | NIH/NICHD |
| Role: | Contact Principal Investigator |
| ID: | R01HD110520 |
| Date: | 2023 - 2028 |
| Title: | Molecular Mechanisms of Bladder Cancer Immunometabolism |
| Funding Source: | NIH/NCI |
| Role: | Contact Principal Investigator |
| ID: | CA269489 |
Selected Publications
Peer-Reviewed Articles
- Wang, R, Luo, M, Liu, Y, Yang, J, Chen, Y, Chen, C, Ma, L, Ding, S, Wengler, J, Zang, Y, Lim, B, Li, W, Yang, L, Lin, C, Diao, L, Han, L. Functional, Pharmacogenomic, and Immune Landscapes of Long Non-Coding RNAs in Cancer. Advanced Science 13(6), 2026. e-Pub 2026. PMID: 41270088.
- Wang, S, Liang, K, Hu, Q, Li, P, Song, J, Yang, Y, Yao, J, Mangala, LS, Li, C, Yang, W, Park, PK, Hawke, DH, Zhou, J, Zhou, Y, Xia, W, Hung, M, Marks, JR, Gallick, GE, Lopez Berestein, G, Flores, ER, Sood, AK, Huang, S, Yu, D, Yang, L, Lin, C. Expression of Concern for JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. Journal of Clinical Investigation 135(19), 2025. e-Pub 2025. PMID: 41031879.
- Chen, MK, Yamaguchi, H, Gao, Y, Xia, W, Chang, J, Hsiao, YC, Shegute, TW, Lin, ZS, Wu, CS, Wang, YH, Litton, J, Ding, Q, Wei, Y, Chu, Y, Meric-Bernstam, F, Piwnica-Worms, H, Arun, BK, Ahnert, JR, Liu, J, Yao, J, Chang, W, Wang, HL, Tapia, C, Albarracin, C, Keyomarsi, K, Wang, SC, Wang, Y, Hortobagyi, GN, Lin, C, Yang, L, Yu, D, Hung, M. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. Journal of Clinical Investigation 135(14), 2025. e-Pub 2025. PMID: 40460005.
- Zhao, Z, Hu, B, Deng, Y, Soeung, M, Yao, J, Bei, L, Zhang, Y, Gong, P, Huang, L, Jiang, Z, Gao, J, Peng, S, Nguyen, TK, Karki, M, Lim, B, Yee, C, Burks, JK, Zhang, Q, Ma, L, Gao, J, Tannir, NM, Han, L, Yu, D, Wang, L, Curran, M, Gubbiotti, M, Genovese, G, Gan, B, Li, W, Msaouel, P, Yang, L, Lin, C. Sickle cell disease induces chromatin introversion and ferroptosis in CD8+ T cells to suppress anti-tumor immunity. Immunity 58(6):1484-1501.e11, 2025. e-Pub 2025. PMID: 40359940.
- Wang, R, Chen, C, Liu, Y, Luo, M, Yang, J, Chen, Y, Ma, L, Yang, L, Lin, C, Diao, L, Han, L. The pharmacogenomic and immune landscape of snoRNAs in human cancers. Cancer Letters 605, 2024. e-Pub 2024. PMID: 39426663.
- Wang R, Chen C, Liu Y, Luo M, Yang J, Chen Y, Ma L, Yang L, Lin C, Diao L, Han L. The pharmacogenomic and immune landscape of snoRNAs in human cancers. Cancer Letters 605, 2024. e-Pub 2024.
- Xun Z, Zhou H, Shen M, Liu Y, Sun C, Du Y, Jiang Z, Yang L, Zhang Q, Lin C, Hu Q, Ye Y, Han L. Identification of Hypoxia-ALCAM high Macrophage- Exhausted T Cell Axis in Tumor Microenvironment Remodeling for Immunotherapy Resistance. Advanced Science 11(33), 2024. e-Pub 2024. PMID: 38956900.
- Zhang Y, Zhao Z, Huang LA, Liu Y, Yao J, Sun C, Li Y, Zhang Z, Ye Y, Yuan F, Nguyen TK, Garlapati NR, Wu A, Egranov SD, Caudle AS, Sahin AA, Lim B, Beretta L, Calin GA, Yu D, Hung MC, Curran MA, Rezvani K, Gan B, Tan Z, Han L, Lin C, Yang L. Molecular mechanisms of snoRNA-IL-15 crosstalk in adipocyte lipolysis and NK cell rejuvenation. Cell Metab 35(8):1457-1473.e13, 2023. e-Pub 2023. PMID: 37329887.
- Sun, C, Ye, Y, Tan, Z, Liu, Y, Li, Y, Hu, W, Liang, K, Egranov, SD, Huang, L, Zhang, Z, Zhang, Y, Yao, J, Nguyen, TK, Zhao, Z, Wu, A, Marks, JR, Caudle, AS, Sahin, AA, Gao, J, Gammon, ST, Piwnica-Worms, D, Hu, J, Chiao, PJ, Yu, D, Hung, MC, Curran, M, Calin, GA, Ying, H, Han, L, Lin, C, Yang, L. Tumor-associated nonmyelinating Schwann cell-expressed PVT1 promotes pancreatic cancer kynurenine pathway and tumor immune exclusion. Science Advances 9(5), 2023. e-Pub 2023. PMID: 36724291.
- Zhang Y, Sun C, Li Y, Qin J, Amancherla K, Jing Y, Hu Q, Liang K, Zhang Z, Ye Y, Huang LA, Nguyen TK, Egranov SD, Zhao Z, Wu A, Xi Y, Yao J, Hung MC, Calin GA, Cheng J, Lim B, Lehmann LH, Salem JE, Johnson DB, Curran MA, Yu D, Han L, Darabi R, Yang L, Moslehi JJ, Lin C. Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 14(669), 2022. e-Pub 2022. PMID: 36322628.
- Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
- Cha, JH, Chan, LC, Wang, Y, Chu, YY, Wang, CH, Lee, H, Xia, W, Shyu, WC, Liu, S, Yao, J, Chang, CW, Cheng, FR, Liu, J, Lim, S, Hsu, JL, Yang, W, Hortobagyi, GN, Lin, C, Yang, L, Yu, D, Jeng, LB, Hung, MC. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. Journal of Biological Chemistry 298(4), 2022. e-Pub 2022. PMID: 35278434.
- Shih DJH, Chen MK, Yin J, McGrail DJ, Dai H, Wei R, Zhang J, Zheng WJ, Do KA, Yang L, Hung MC, Lin SY. Exploiting induced vulnerability to overcome PARPi resistance and clonal heterogeneity in BRCA mutant triple-negative inflammatory breast cancer. Am J Cancer Res 12(1):337-354, 2022. e-Pub 2022. PMID: 35141022.
- Li Y, Zhang Y, Hu Q, Egranov SD, Xing Z, Zhang Z, Liang K, Ye Y, Pan Y, Chatterjee SS, Mistretta B, Nguyen TK, Hawke DH, Gunaratne PH, Hung MC, Han L, Yang L, Lin C. Functional significance of gain-of-function H19 lncRNA in skeletal muscle differentiation and anti-obesity effects. Genome Med 13(1):137, 2021. e-Pub 2021. PMID: 34454586.
- Zhang, Y, Li, B, Bai, Q, Wang, P, Wei, G, Li, Z, Hu, L, Tian, Q, Zhou, J, Huang, Q, Wang, Z, Yue, S, Wu, J, Yang, L, Zhou, X, Jiang, L, Ni, T, Ye, L, Wu, Y. The lncRNA Snhg1-Vps13D vesicle trafficking system promotes memory CD8 T cell establishment via regulating the dual effects of IL-7 signaling. Signal Transduction and Targeted Therapy 6(1), 2021. e-Pub 2021. PMID: 33758164.
- Li Y, Tan Z, Zhang Y, Zhang Z, Hu Q, Liang K, Jun Y, Ye Y, Li YC, Li C, Liao L, Xu J, Xing Z, Pan Y, Chatterjee SS, Nguyen TK, Hsiao H, Egranov SD, Putluri N, Coarfa C, Hawke DH, Gunaratne PH, Tsai KL, Han L, Hung MC, Calin GA, Namour F, Guéant JL, Muntau AC, Blau N, Sutton VR, Schiff M, Feillet F, Zhang S, Lin C, Yang L. A noncoding RNA modulator potentiates phenylalanine metabolism in mice. Science 373(6555):662-673, 2021. e-Pub 2021. PMID: 34353949.
- Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 131(8), 2021. e-Pub 2021. PMID: 33855973.
- Zhang Y, Li Y, Hu Q, Xi Y, Xing Z, Zhang Z, Huang L, Wu J, Liang K, Nguyen TK, Egranov SD, Sun C, Zhao Z, Hawke DH, Li J, Sun D, Kim JJ, Zhang P, Cheng J, Farida A, Hung MC, Han L, Darabi R, Lin C, Yang L. The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol 22(11):1332-1345, 2020. e-Pub 2020. PMID: 33106653.
- Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi MP, Huo L, Scott A, Wang Y, Ma L, Lee JH, Bhutani MS, Weston B, Vellano C, Yang L, Lin C, Kim Y, MacLeod AR, Wang L, Wang Z, Song S, Ajani JA. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer 18(1):141, 2019. e-Pub 2019. PMID: 31601234.
- Hu Q, Ye Y, Chan LC, Li Y, Liang K, Lin A, Egranov SD, Zhang Y, Xia W, Gong J, Pan Y, Chatterjee SS, Yao J, Evans KW, Nguyen TK, Park PK, Liu J, Coarfa C, Donepudi SR, Putluri V, Putluri N, Sreekumar A, Ambati CR, Hawke DH, Marks JR, Gunaratne PH, Caudle AS, Sahin AA, Hortobagyi GN, Meric-Bernstam F, Chen L, Yu D, Hung MC, Curran MA, Han L, Lin C, Yang L. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol 20(7):835-851, 2019. e-Pub 2019. PMID: 31160797.
- Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, Ruan H, Zhang Z, Song A, Zhang H, Liu L, Diao L, Lou Y, Zhou B, Wang L, Zhou S, Gao J, Jonasch E, Lin SH, Xia Y, Lin C, Yang L, Mills GB, Liang H, Han L. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nature Metabolism 1(4):431-444, 2019. e-Pub 2019. PMID: 31984309.
- Li Y, Hu Q, Li C, Liang K, Xiang Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Ambati CR, Putluri N, Hawke DH, Han L, Hung MC, Danesh FR, Yang L, Lin C. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J Clin Invest 129(3):1129-1151, 2019. e-Pub 2019. PMID: 30741721.
- Hu Q, Li C, Wang S, Li Y, Wen B, Zhang Y, Liang K, Yao J, Ye Y, Hsiao H, Nguyen TK, Park PK, Egranov SD, Hawke DH, Marks JR, Han L, Hung MC, Zhang B, Lin C, Yang L. LncRNAs-directed PTEN enzymatic switch governs epithelial-mesenchymal transition. Cell Res 29(4):286-304, 2019. e-Pub 2019. PMID: 30631154.
- Xing Z, Zhang Y, Liang K, Yan L, Xiang Y, Li C, Hu Q, Jin F, Putluri V, Putluri N, Coarfa C, Sreekumar A, Park PK, Nguyen TK, Wang S, Zhou J, Zhou Y, Marks JR, Hawke DH, Hung MC, Yang L, Han L, Ying H, Lin C. Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res 78(16):4524-4532, 2018. e-Pub 2018. PMID: 29967256.
- Wang S, Liang K, Hu Q, Li P, Song J, Yang Y, Yao J, Mangala LS, Li C, Yang W, Park PK, Hawke DH, Zhou J, Zhou Y, Xia W, Hung MC, Marks JR, Gallick GE, Lopez-Berestein G, Flores ER, Sood AK, Huang S, Yu D, Yang L, Lin C. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. J Clin Invest 127(12):4498-4515, 2017. e-Pub 2017. PMID: 29130936.
- Gong J, Li Y, Liu CJ, Xiang Y, Li C, Ye Y, Zhang Z, Hawke DH, Park PK, Diao L, Putkey JA, Yang L, Guo AY, Lin C, Han L. A Pan-cancer Analysis of the Expression and Clinical Relevance of Small Nucleolar RNAs in Human Cancer. Cell Rep 21(7):1968-1981, 2017. e-Pub 2017. PMID: 29141226.
- Lin A, Hu Q, Li C, Xing Z, Ma G, Wang C, Li J, Ye Y, Yao J, Liang K, Wang S, Park PK, Marks JR, Zhou Y, Zhou J, Hung MC, Liang H, Hu Z, Shen H, Hawke DH, Han L, Zhou Y, Lin C, Yang L. The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. Nat Cell Biol 19(3):238-251, 2017. e-Pub 2017. PMID: 28218907.
- Li C, Wang S, Xing Z, Lin A, Liang K, Song J, Hu Q, Yao J, Chen Z, Park PK, Hawke DH, Zhou J, Zhou Y, Zhang S, Liang H, Hung MC, Gallick GE, Han L, Lin C, Yang L. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. Nat Cell Biol 19(2):106-119, 2017. e-Pub 2017. PMID: 28114269.
- Jain AK, Xi Y, McCarthy R, Allton K, Akdemir KC, Patel LR, Aronow B, Lin C, Li W, Yang L, Barton MC. LncPRESS1 Is a p53-Regulated LncRNA that Safeguards Pluripotency by Disrupting SIRT6-Mediated De-acetylation of Histone H3K56. Mol Cell 64(5):967-981, 2016. e-Pub 2016. PMID: 27912097.
- Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, Hu Z, Zhou Y, Marks JR, Liang H, Hung MC, Lin C, Yang L. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer. Nat Cell Biol 18(2):213-24, 2016. e-Pub 2016. PMID: 26751287.
- Li N, Zhang Y, Han X, Liang K, Wang J, Feng L, Wang W, Songyang Z, Lin C, Yang L, Yu Y, Chen J. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev 29(2):157-70, 2015. e-Pub 2015. PMID: 25547115.
- Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, Park PK, Qin L, Wei Y, Hawke DH, Hung MC, Lin C, Yang L. lncRNA directs cooperative epigenetic regulation downstream of chemokine signals. Cell 159(5):1110-25, 2014. e-Pub 2014. PMID: 25416949.
- Jin C, Yang L, Xie M, Lin C, Merkurjev D, Yang JC, Tanasa B, Oh S, Zhang J, Ohgi KA, Zhou H, Li W, Evans CP, Ding S, Rosenfeld MG. Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens. PNAS 111(25):9235-9240, 2014. e-Pub 2014. PMID: 24928520.
- Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 500(7464):598-602, 2013. e-Pub 2013. PMID: 23945587.
- Yang L, Lin C, Liu W, Zhang J, Ohgi KA, Grinstein JD, Dorrestein PC, Rosenfeld MG. ncRNA- and Pc2 methylation-dependent gene relocation between nuclear structures mediates gene activation programs. Cell 147(4):773-88, 2011. e-Pub 2011. PMID: 22078878.
- Carter CL, Lin C, Liu CY, Yang L, Liu ZR. Phosphorylated p68 RNA helicase activates Snail1 transcription by promoting HDAC1 dissociation from the Snail1 promoter. Oncogene 29(39):5427-36, 2010. e-Pub 2010. PMID: 20676135.
- Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, Zhang J, Rose DW, Fu XD, Glass CK, Rosenfeld MG. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 139(6):1069-83, 2009. e-Pub 2009. PMID: 19962179.
- Yang L, Lin C, Sun SY, Zhao S, Liu ZR. A double tyrosine phosphorylation of P68 RNA helicase confers resistance to TRAIL-induced apoptosis. Oncogene 26(41):6082-92, 2007. e-Pub 2007. PMID: 17384675.
- Yang L, Lin C, Zhao S, Wang H, Liu ZR. Phosphorylation of p68 RNA helicase plays a role in platelet-derived growth factor-induced cell proliferation by up-regulating cyclin D1 and c-Myc expression. J Biol Chem 282(23):16811-9, 2007. e-Pub 2007. PMID: 17412694.
- Yang L, Lin C, Liu ZR. P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin. Cell 127(1):139-55, 2006. e-Pub 2006. PMID: 17018282.
- Yang L, Lin C, Liu ZR. Signaling to the DEAD box--regulation of DEAD-box p68 RNA helicase by protein phosphorylations. Cell Signal 17(12):1495-504, 2005. e-Pub 2005. PMID: 15927448.
- Lin C, Yang L, Yang JJ, Huang Y, Liu ZR. ATPase/helicase activities of p68 RNA helicase are required for pre-mRNA splicing but not for assembly of the spliceosome. Mol Cell Biol 25(17):7484-93, 2005. e-Pub 2005. PMID: 16107697.
- Yang L, Lin C, Liu ZR. Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation. Mol Cancer Res 3(6):355-63, 2005. e-Pub 2005. PMID: 15972854.
- Yang L, Liu ZR. Bacterially expressed recombinant p68 RNA helicase is phosphorylated on serine, threonine, and tyrosine residues. Protein Expr Purif 35(2):327-33, 2004. e-Pub 2004. PMID: 15135410.
- Yang L, Yang J, Huang Y, Liu ZR. Phosphorylation of p68 RNA helicase regulates RNA binding by the C-terminal domain of the protein. Biochem Biophys Res Commun 314(2):622-30, 2004. e-Pub 2004. PMID: 14733953.
Invited Articles
- Lin C, Yang L. Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends Cell Biol 28(4):287-301, 2018. e-Pub 2018. PMID: 29274663.
- Li C, Yang L, Lin C. Long noncoding RNAs in Prostate Cancer: Mechanisms and Applications. Mol Cell Oncol 1(3):e963469, 2014. e-Pub 2014. PMID: 27308347.
- Yang L, Lin C, Rosenfeld MG. A lincRNA switch for embryonic stem cell fate. Cell Res 21(12):1646-8, 2011. e-Pub 2011. PMID: 22025254.
Review Articles
- Huang, L, Lin, C, Yang, L. Plumbing mysterious RNAs in “dark genome” for the conquest of human diseases. Molecular Therapy 31(6):1577-1595, 2023. e-Pub 2023. PMID: 37165619.
- Hu Q, Egranov SD, Lin C, Yang L. Long noncoding RNA loss in immune suppression in cancer. Pharmacol Ther 213, 2020. e-Pub 2020. PMID: 32473960.
- Egranov SD, Hu Q, Lin C, Yang L. LncRNAs as tumor cell intrinsic factors that affect cancer immunotherapy. RNA Biol 17(11):1625–1627, 2020. e-Pub 2020. PMID: 32449433.
- Xing Z, Park PK, Lin C, Yang L. LncRNA BCAR4 wires up signaling transduction in breast cancer. RNA Biol 12(7):681-9, 2015. e-Pub 2015. PMID: 26016563.
Editorials
- Shiu, PK, Ilieva, M, Holm, A, Uchida, S, DiStefano, JK, Bronisz, A, Yang, L, Asahi, Y, Goel, A, Yang, L, Nuthanakanti, A, Serganov, A, Alahari, SK, Lin, C, Pardini, B, Naccarati, A, Jin, J, Armanios, B, Zhong, XB, Sideris, N, Bayraktar, S, Castellano, L, Gerber, AP, Lin, H, Conn, SJ, Sleem, DM, Timmons, L. The Non-Coding RNA Journal Club. Non-coding RNA 9(2), 2023. PMID: 37104010.
Book Chapters
- Xing, Z, Egranov, SD, Lin, C, Yang, L. LncRNA Pulldown Combined with Mass Spectrometry to Identify the Novel lncRNA-Associated Proteins, 1-10, 2021.
- Lin C, Yang L, Rosenfeld MG. Molecular logic underlying chromosomal translocations, random or non-random?. In: Adv Cancer Res, 241-79, 2012.
Patient Reviews
CV information above last modified July 22, 2026